Corcept Therapeutics Inc
CORT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.87B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.87 Billion |
|---|---|
| Enterprise Value | $7.78 Billion |
| Earnings per Share | $0.95 |
| Beta | 0.45 |
| Outstanding Shares | 106,628,000 |
Return
| Return on Equity | 19.43% |
|---|---|
| Return on Assets | 15.67% |
| Return on Invested Capital | 14.78% |
Valuation & Multiples
| P/E Ratio | 48.51 |
|---|---|
| PEG | 8.74 |
| Price to Sales | 8.1 |
| Price to Book Ratio | 10.42 |
| Enterprise Value to Revenue | 8.07 |
| Enterprise Value to EBIT | 61.48 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$0.79
Consensus analyst estimateRevenue Estimate
$323.90 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
$1.12
Consensus analyst estimateRevenue Estimate
$396.63 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 1.25, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.
| Put/Call Ratio | 1.2500▲ 98.37% |
|---|---|
| Total Calls | 2,000▼ 99.88% |
| Total Puts | 2,500▼ 99.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.27%▼ 68.00% |
|---|---|
| Total Invested | $1.36B▼ 81.31% |
| Investors Holding | 218▼ 233.00% |
About Corcept Therapeutics Inc
730 employees
CEO: Joseph Belanoff
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...